Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002378 · ClinicalTrials.gov registry record · Phase 1
The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01002378 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 24 participants.
The verdict
NCT01002378, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002378
The ClinicalTrials.gov registry entry for NCT01002378 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT01002378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002378 about?
NCT01002378 is a clinical study titled "The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib". An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
What is the current status of trial NCT01002378?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT01002378?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT01002378?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.